Medicrea was issued seven additional patents related to its proprietary UNiD™ ASI (Adaptive Spine Intelligence) technology platform that augments procedures with tools for data management, artificial intelligence and predictive modeling.
The U.S. patents (10,441,363; 10,433,912; 10,420,615; 10,433,913; 10,426,553; 10,413,365 and 10,456,211) relate to fundamental technologies and methods embedded in UNiD ASI, primarily methods, systems and devices for designing and manufacturing a spinal rod, and also methods and apparatus for spinal reconstructive surgery and measurement of spinal length and intervertebral spacing, tension and rotation.
CEO Denys Sournac said, “With over 5,000 cases performed through the UNiD ASI technology platform, all including patient-specific implants, this technology undoubtedly met a market need. The new U.S. patents issued create strong barriers to entry for competitors. It enables the company to maintain its competitive advantage and strengthen its leading position in the marketplace that is now obviously evolving into this direction.”
Medicrea was issued seven additional patents related to its proprietary UNiD™ ASI (Adaptive Spine Intelligence) technology platform that augments procedures with tools for data management, artificial intelligence and predictive modeling.
The U.S. patents (10,441,363; 10,433,912; 10,420,615; 10,433,913; 10,426,553; 10,413,365...
Medicrea was issued seven additional patents related to its proprietary UNiD™ ASI (Adaptive Spine Intelligence) technology platform that augments procedures with tools for data management, artificial intelligence and predictive modeling.
The U.S. patents (10,441,363; 10,433,912; 10,420,615; 10,433,913; 10,426,553; 10,413,365 and 10,456,211) relate to fundamental technologies and methods embedded in UNiD ASI, primarily methods, systems and devices for designing and manufacturing a spinal rod, and also methods and apparatus for spinal reconstructive surgery and measurement of spinal length and intervertebral spacing, tension and rotation.
CEO Denys Sournac said, “With over 5,000 cases performed through the UNiD ASI technology platform, all including patient-specific implants, this technology undoubtedly met a market need. The new U.S. patents issued create strong barriers to entry for competitors. It enables the company to maintain its competitive advantage and strengthen its leading position in the marketplace that is now obviously evolving into this direction.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
